Arrowhead Pharmaceuticals, Inc. ARWR

ARWR Company Overview

Arrowhead Pharmaceuticals, Inc. is a publicly traded biotechnology company focused on the discovery and development of RNA interference (RNAi)–based medicines. The company operates within the biotechnology and pharmaceutical industries, specifically targeting diseases driven by the production of pathogenic proteins. Arrowhead’s core strategy is to design RNAi therapeutics that silence disease-causing genes at the source, with a primary focus on cardiometabolic, hepatic, pulmonary, and rare genetic diseases.

The company’s primary value drivers are its proprietary RNAi delivery platforms and a pipeline of clinical and preclinical drug candidates, most of which are wholly owned. Arrowhead does not currently generate product revenue and instead relies on research collaborations, licensing agreements, and equity financing to support operations. Founded in 2003 and originally focused on nanotechnology, Arrowhead pivoted in the late 2000s to RNAi therapeutics, evolving into a clinical-stage biotechnology company with multiple assets in human trials.